I think people have become psychologically attached to NEJM, when the Lancet seems more likely based upon some recent articles on ECAs and proper censorship. Anyway, most people think those two have the highest impact factors; they don’t, there is one even higher.
Well, the standard advice is to buy on the way up, so you’re probably right - fairly safe under $1.00. The new shares I buy know are just meant to be held short term.